BridgeMD
A trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis.
EU CTIS ID: 2025-523051-64-00
What this study is testing
To explore the efficacy of IDOR-1117-2520, compared to placebo, on Psoriasis Area and Severity Index (PASI) score in participants with moderate to severe chronic plaque psoriasis.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Stable moderate to severe chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months (clinical diagnosis) before screening.
- • Psoriasis Area and Severity Index (PASI) score ≥ 12, static physician’s global assessment (sPGA) score ≥ 3, and affected body surface area ≥ 10 % at both Screening and randomization.
- • Participant must be a candidate for systemic therapy, including phototherapy, for psoriasis treatment, as judged by the investigator.
- • For participants of childbearing potential: - have a negative pregnancy test at Screening and at randomization - agree to use a highly effective method of contraception from Screening up to 30 days after permanent trial intervention discontinuation, be sexually inactive, or have a vasectomized partner - agree to undertake monthly urine pregnancy tests during the trial and up to at least 30 days after discontinuation of trial intervention.
You likely can't join if
- • Any other significant clinically unstable medical condition, or acute illness within 1 month prior to Screening, that, in the investigator’s opinion, could interfere with the participant’s ability to comply with trial assessments or abide by trial restrictions.
- • Generalized erythrodermic, generalized pustular (von Zumbusch), guttate, scalp only, and palmo-plantar psoriasis only.
- • Current drug-induced psoriasis (including a new onset or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium).
- • Active skin infections (e.g., sores, blisters) or concurrent skin disease (e.g., acne) of significant severity which could potentially interfere with the trial evaluation (e.g., evaluation of skin pathology) or any other skin comorbidities that could interfere with trial assessments.
The study team makes the final eligibility decision.
Where it's taking place
- Ukraine
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ukraine. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.